Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment

Fig. 4

The genotypes of p53 codon 72 variants and Kaplan-Meier plots of OS for three groups of GBM patients are presented. a Comparison of the estimated OS for patients with tumor specimens with the p53 codon 72 Pro/Pro genotypes among those treated with CCRT and those treated with CCRT plus bevacizumab. b The estimated OS for patients with tumor specimens with the Arg/Arg genotypes of p53 codon 72 for CCRT and CCRT plus bevacizumab treatment. c The estimated OS for patients with tumor specimens with the heterozygous Arg/Pro genotypes of p53 codon 72 for CCRT and CCRT plus bevacizumab treatment. ** indicates p < 0.001

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us